61 results
Page 2 of 4
8-K
EX-99.1
lfi7q lcvibgoejpt6e
29 Jun 23
Other Events
7:08am
8-K
EX-99.1
ivlq824o
11 May 23
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
4:08pm
DEF 14A
vu88oe9
10 Apr 23
Definitive proxy
4:07pm
PRE 14A
3jr5g
31 Mar 23
Preliminary proxy
4:36pm
8-K
EX-99.1
u61bxhgmhzhgmnusvu
17 Nov 22
Invivyd Announces Partnership with Population Health Partners to Accelerate Clinical Development In Infectious Diseases Including COVID-19
7:10am
8-K
EX-99.1
y61omo
13 Oct 22
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery
4:16pm
S-3
izsmm7cbcs64k
28 Sep 22
Shelf registration
5:08pm
8-K
EX-99.1
wcvf4xs00kfdr2u7csa0
12 Sep 22
Adagio Therapeutics Announces Corporate Name Change to Invivyd
7:46am
8-K
EX-99.3
fneco2sh5kzp
12 Sep 22
Adagio Therapeutics Announces Corporate Name Change to Invivyd
7:46am
8-K
EX-99.1
tt89m31kax
15 Aug 22
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
7:22am
8-K
av5yvauul2rgt0y5489m
22 Jun 22
Submission of Matters to a Vote of Security Holders
5:18pm
DEFC14C
p0oqo4sg2s4
2 Jun 22
Information statement in contested solicitation
4:24pm
PRER14C
hvuq 1cccppjuzpj
31 May 22
Preliminary revised information
5:09pm
PREC14C
d5mhglpmhmaht00f3 44
19 May 22
Preliminary information statement in contested solicitation
5:05pm
10-K/A
x3gus eu1
29 Apr 22
Annual report (amended)
4:43pm
DEFC14A
3gk13sosnjteli
29 Apr 22
Proxy in contested solicitation
4:02pm